Drug intelligence / Profile preview

montelukast + favipiravir

Development stage: Preclinical
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

A combination of montelukast, a leukotriene receptor antagonist used for asthma and allergies, and favipiravir, an antiviral that inhibits viral RNA-dependent RNA polymerase. The combination has been studied for potential synergistic effects in treating COVID-19. Favipiravir can decrease the metabolism of montelukast by inhibiting Cytochrome P450 (CYP2C8), potentially increasing montelukast's bioavailability. Montelukast has shown potential to bind to and block SARS-CoV-2 proteins, while favipiravir inhibits viral replication.

Targets

CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)RdRp (Coronavirus RNA-dependent RNA polymerase)CYP2C8 (Cytochrome P450 2C8)

Beyond the preview

Go deeper on montelukast + favipiravir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on montelukast + favipiravir.

Explore the full profile